Skip to main content
. 2015 Sep 22;2015(9):CD001191. doi: 10.1002/14651858.CD001191.pub4

5. Comparison of different methods of dealing with missing values.

Time point population rivastigmine n placebo n result probability level 95% confidence limits
1 to 4 mg daily versus placebo, ADAS‐Cog measured as change from baseline
12 weeks ITT 650 643 favours rivastigmine WMD ‐0.31 0.30 ‐0.87, 0.25
OC 589 598 favours rivastigmine WMD ‐0.46 0.14 ‐1.08, 0.15
RDO + OC 616 615 favours rivastigmine WMD ‐0.37 0.20 ‐0.96, 0.23
18 weeks ITT 650 643 favours rivastigmine WMD ‐1.07 0.0004 ‐1.66, ‐0.48
OC 558 552 favours rivastigmine WMD ‐1.19 0.0005 ‐1.86, ‐0.52
RDO + OC 573 572 favours rivastigmine WMD ‐1.33 0.00008 ‐1.99, ‐0.67
26 weeks ITT 650 644 favours rivastigmine WMD ‐0.84 0.01 ‐1.48, ‐0.19
OC 519 526 favours rivastigmine WMD ‐0.96 0.01 ‐1.72, ‐0.21
RDO + OC 559 564 favours rivastigmine WMD ‐1.07 0.004 ‐1.80, ‐0.34
6 to 12 mg daily versus placebo, ADAS‐Cog measured as change from baseline
12 weeks ITT 1054 863 favours rivastigmine WMD ‐1.49 <0.00001 ‐1.96, ‐1.01
OC 843 803 favours rivastigmine WMD ‐1.80 <0.00001 ‐2.33, ‐1.27
RDO + OC 967 828 favours rivastigmine WMD ‐1.38 <0.00001 ‐1.89, ‐0.88
6 to 12 mg daily versus placebo, ADAS‐Cog measured as change from baseline
18 weeks ITT 1054 863 favours rivastigmine WMD ‐1.79 <0.00001 ‐2.30,‐ 1.29
OC 732 742 favours rivastigmine WMD ‐2.36 <0.00001 ‐2.96, ‐1.76
RDO + OC 837 772 favours rivastigmine WMD ‐2.12 <0.00001 ‐2.69, ‐1.55
26 weeks ITT 1054 863 favours rivastigmine WMD ‐2.09 <0.00001 ‐2.65, ‐1.54
OC 670 709 favours rivastigmine WMD ‐2.62 <0.00001 ‐3.29, ‐1.94
RDO + OC 788 759 favours rivastigmine WMD ‐2.39 <0.00001 ‐3.03, ‐1.74
1 to 4 mg daily versus placebo, CIBIC‐Plus measured as no change or worse
12 weeks ITT 608 612 favours rivastigmine
Peto OR 0.93
0.60 0.72, 1.21
OC 583 596 favours rivastigmine
Peto OR 0.95
0.70 0.72, 1.23
RDO + OC 609 612 favours rivastigmine
Peto OR 0.94
0.60 0.72, 1.22
18 weeks ITT 614 620 favours rivastigmine
Peto OR 0.98
0.90 0.75, 1.26
OC 556 554 favours placebo
Peto OR 1.04
0.80 0.80, 1.37
RDO + OC 570 576 favours placebo
Peto OR 1.02
0.90 0.78, 1.34
26 weeks ITT 614 623 favours rivastigmine
Peto OR 0.71
0.01 0.55, 0.93
OC 513 523 favours rivastigmine
Peto OR 0.67
0.006 0.50, 0.89
RDO + OC 544 549 favours rivastigmine
Peto OR 0.68
0.008 0.52, 0.91
1 to 4 mg daily versus placebo, CIBIC‐Plus measured as no change or worse
12 weeks ITT 950 825 favours rivastigmine
Peto OR 0.74
0.008 0.60, 0.92
OC 831 799 favours rivastigmine
Peto OR 0.72
0.005 0.58, 0.91
RDO + OC 952 825 favours rivastigmine
Peto OR 0.75
0.01 0.60, 0.93
18 weeks ITT 970 835 favours rivastigmine
Peto OR 0.81
0.06 0.65, 1.01
OC 720 741 favours rivastigmine
Peto OR 0.72
0.005 0.57, 0.91
RDO + OC 820 772 favours rivastigmine
Peto OR 0.77
0.02 0.62, 0.97
26 weeks ITT 973 839 favours rivastigmine
Peto OR 0.68
0.0007 0.55, 0.85
OC 660 693 favours rivastigmine
Peto OR 0.63
0.0004 0.49, 0.81
RDO + OC 784 758 favours rivastigmine
Peto OR 0.65
0.0003 0.51, 0.82

The results for two outcomes, ADAS‐Cog and CBIC at 12, 18 and 26 weeks, have been pooled for 3 studies, B303/B305, B351. B352. These studies reported results for 3 populations, intention‐to‐treat (ITT), completers (OC), and completers + retrieved dropout (RDO + OC). The table reports the results of the meta‐analyses for 2 comparisons (1 to 4 mg daily versus placebo and 6 to 12 mg/day versus placebo) for the 3 populations at the 3 time points.